Hansen Medical (NSDQ:HNSN) said its Magellan surgical robotics system was used in the 1st robotic fibroid embolization performed in the U.S.
European physicians have already used the Magellan system for uterine fibroid embolizations. Recent FDA clearance of a smaller catheter allowed for the procedure to be performed here in the smaller blood vessels of the uterus, according to a press release.
Mountain View, Calif.-based Hansen said the U.S. operation was performed by Dr. Sandeep Rao at the Sierra Medical Center in El Paso, Texas.
"I am extremely pleased by the outcome of this initial procedure," Rao said in prepared remarks. "Robotic catheters have the potential to provide enhanced control and precision, especially in the small, often tortuous blood vessels involved in UFE. The Magellan system enables us to offer a compelling, non-surgical, robotic treatment option for a condition affecting a large number of women."
"Congratulations to Dr. Rao and the entire team at Sierra Medical Center on this exciting milestone," added president & CEO Cary Vance. "With the recent introduction of the new 6Fr robotic catheter, physicians and hospitals are now able to broaden their use of Magellan and apply the benefits of robotic control and precision to intravascular procedures in smaller blood vessels, including UFE."
Hansen sold 3 Magellan systems and 1 Sensei X system en route to $6.9 million in 2nd-quarter revenue and a $12.3 million loss. In July Hansen said it raised $23 million in a warrants offering.
"We added a number of salespeople last year and the beginning of this year that are now starting to ramp up," Vance told analysts during a conference call discussing the Q2 results. "We’ve got great technology, we’ve got great IP – we own the space. We’ve got great people here that are passionate about it who have a great level of accountability and are aggressively pursuing the goals we have as a company."